GNI Group Ltdの最新の1株当たり利益は$-70.34で、$226.88の予想を殴打しない。
GNI Group Ltd GNIIFの前四半期の収益はどうでしたか?
GNI Group Ltdの前四半期の収益は$-70.34です。
GNI Group Ltdの収益見積もりはいくらですか?
人のウォール街のアナリストによると、GNI Group Ltdの収益見積もりは$から$の範囲です。
GNI Group Ltdの収益品質スコアはどれくらいですか?
GNI Group Ltdの収益品質スコアは/です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
GNI Group Ltdはいつ収益を報告しますか?
GNI Group Ltdの次の収益報告は2026-05-14に予定されています
GNI Group Ltdの予想収益はいくらですか?
ウォール街のアナリストによると、GNI Group Ltdの予想収益は$11.52Bです。
GNI Group Ltdは収益予想を上回りましたか?
GNI Group Ltdの最近の収益は$7.48Bで、予想をビート。
主要データ
前終値
$15.5
始値
$15.5
当日レンジ
$15.5 - $15.5
52週レンジ
$12.02 - $19.1
取引高
100
平均取引高
0
配当利回り
--
1株当たり利益(TTM)
-0.02
時価総額
$863.1M
GNI GROUP LTDとは何ですか?
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2007-08-31. The firm conducts global pharmaceutical research and development, manufacturing and distribution and biomaterials business. The firm operates in two business segments. The Pharmaceuticals segment conducts research and development, manufacturing, and sale of developed compounds, including ETUARY sold in the China market and Hydronidone (F351), which is in clinical trials. The main products also include other pharmaceuticals and reagents. The Medical Devices segment develops, manufactures, and sells medical devices such as biomaterials in the United States. This segment also includes medical device Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) services. The firm also conducts clinical and business development in the United States and conducts clinical development of F351 for Metabolic Dysfunction-Associated Steatohepatitis in the United States.